Patents by Inventor CAROLE BELANGER

CAROLE BELANGER has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical compositions for combination therapy
    Patent number: 11590108
    Abstract: The present invention relates to a combination of active ingredients for use in the treatment of diseases.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: February 28, 2023
    Assignee: Genfit
    Inventors: Emeline Descamps, Robert Walczak, Carole Belanger, Benoît Noel
  • Combination comprising a PPAR agonist such as elafibranor and an acetyl-CoA carboxylase (ACC) inhibitor
    Patent number: 11484517
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: November 1, 2022
    Assignee: GENFIT
    Inventors: Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak, Isabelle Delbaere
  • Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent
    Patent number: 11478440
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 25, 2022
    Assignee: GENFIT
    Inventors: Robert Walczak, Carole Belanger, Vanessa Legry, Benoît Noel, Emeline Descamps, Guillaume Vidal, Mathilde Walczak
  • IN VITRO MODEL OF LIVER STEATOSIS AND FIBROSING NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20220056419
    Abstract: The present invention relates to compositions and methods for preparing in vitro models of non-alcoholic fatty liver disease, and more particularly of liver steatosis and fibrosing non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: December 18, 2019
    Publication date: February 24, 2022
    Inventors: GUILLAUME VIDAL, FLORIANE LIMOGE, JULIETTE DROUARD, ROBERT WALCZAK, CAROLE BELANGER
  • Pharmaceutical compositions for combination therapy
    Patent number: 11191749
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: March 13, 2018
    Date of Patent: December 7, 2021
    Assignee: GENFIT
    Inventors: Dean Hum, Robert Walczak, Carole Belanger, Corinne Foucart
  • PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
    Publication number: 20210275504
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Application
    Filed: May 10, 2021
    Publication date: September 9, 2021
    Inventors: Corinne FOUCART, Robert WALCZAK, Carole BELANGER, Benoît NOEL
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 11103484
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: June 24, 2020
    Date of Patent: August 31, 2021
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Pharmaceutical compositions for combination therapy
    Patent number: 11033534
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: June 15, 2021
    Assignee: GENFIT
    Inventors: Corinne Foucart, Robert Walczak, Carole Belanger, Benoït Noel
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10905680
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: February 2, 2021
    Assignee: GENFIT
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20200316031
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 8, 2020
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • COMBINATION COMPRISING A PPAR AGONIST SUCH AS ELAFIBRANOR AND AN ACETYL-COA CARBOXYLASE (ACC) INHIBITOR
    Publication number: 20200206169
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Application
    Filed: April 18, 2018
    Publication date: July 2, 2020
    Inventors: ROBERT WALCZAK, CAROLE BELANGER, VANESSA LEGRY, BENOÎT NOEL, EMELINE DESCAMPS, GUILLAUME VIDAL, MATHILDE WALCZAK, ISABELLE DELBAERE
  • COMBINATION OF ELAFIBRANOR OR DERIVATIVES THEREOF WITH AN ANTI-NASH, ANTI-FIBROTIC OR ANTI-CHOLESTATIC AGENT
    Publication number: 20200121625
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Application
    Filed: April 18, 2018
    Publication date: April 23, 2020
    Inventors: ROBERT WALCZAK, CAROLE BELANGER, VANESSA LEGRY, BENOÎT NOEL, EMELINE DESCAMPS, GUILLAUME VIDAL, MATHILDE WALCZAK
  • PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
    Publication number: 20200061028
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Application
    Filed: March 13, 2018
    Publication date: February 27, 2020
    Inventors: Dean HUM, Robert WALCZAK, Carole BELANGER, Corinne FOUCART
  • COMBINATION OF A PPAR AGONIST WITH A FXR AGONIST
    Publication number: 20200054589
    Abstract: The present invention relates to a combination of active ingredients for use in the treatment of diseases.
    Type: Application
    Filed: February 21, 2018
    Publication date: February 20, 2020
    Inventors: Benoît Noel, Robert Walczak, Carole Belanger
  • PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
    Publication number: 20190388398
    Abstract: The present invention relates to a combination product and its use in therapy.
    Type: Application
    Filed: January 29, 2018
    Publication date: December 26, 2019
    Inventors: Corinne FOUCART, Robert WALCZAK, Carole BELANGER, Benoît NOEL
  • PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY
    Publication number: 20190388394
    Abstract: The present invention relates to a combination of active ingredients for use in the treatment of diseases.
    Type: Application
    Filed: February 23, 2018
    Publication date: December 26, 2019
    Inventors: Emeline Descamps, Robert Walczak, Carole Belanger, Benoît Noel
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20190083468
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: December 4, 2018
    Publication date: March 21, 2019
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • METHODS OF TREATMENT FOR CHOLESTATIC AND FIBROTIC DISEASES
    Publication number: 20190000813
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 3, 2019
    Inventors: Raphael DARTEIL, Robert WALCZAK, Carole BELANGER, Emilie NEGRO, Pierre DAUBERSIES, Philippe DELATAILLE
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130612
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille
  • Methods of treatment for cholestatic and fibrotic diseases
    Patent number: 10130613
    Abstract: The present invention relates to the compound [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate (Nitazoxanide) or 2-hydroxy-N-(5-nitro-2-thiazolyl)benzamide (Tizoxanide) for treating cholestatic and fibrotic diseases.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: November 20, 2018
    Assignee: Genfit
    Inventors: Raphael Darteil, Robert Walczak, Carole Belanger, Emilie Negro, Pierre Daubersies, Philippe Delataille